ART and Chronic Kidney Disease

Regimens containing tenofovir with a boosted protease inhibitor were associated with a higher risk for CKD than other regimens, but ART was generally protective against declines in kidney function.

Antiretroviral therapy (ART) is known to reduce the incidence of HIV-associated nephropathy, but concerns remain regarding the potential long-term nephrotoxicity of certain antiretrovirals, such as tenofovir and atazanavir.

To gain a better understanding of the effects of ART regimens on the risk for chronic kidney disease (CKD), researchers evaluated data from more than 3300 HIV-infected adults initiating ART in the U.S. During a median follow-up of 4.8 years (6 months before ART initiation and 2.8 years after), 106 patients developed stage 3 CKD (defined by a decline in estimated glomerular filtration rate [eGFR] to <60 but >30 mL/minute/1.73 m²), and 16 developed stage 4 CKD (defined by a decline in eGFR to <30 mL/minute/1.73 m²); inciden…

Reviewing Author

Sonia Nagy Chimienti, MD

Disclosures

Nothing to disclose

Sonia Nagy Chimienti, MD

Disclosures

Nothing to disclose

ART and Chronic Kidney Disease

Topics

Reviewing Author